These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30562567)

  • 1. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.
    Casseres RG; Kahn JS; Her MJ; Rosmarin D
    J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
    Vekic DA; Frew JW
    Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
    [No Abstract]   [Full Text] [Related]  

  • 3. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases.
    Houriet C; Seyed Jafari SM; Thomi R; Schlapbach C; Borradori L; Yawalkar N; Hunger RE
    JAMA Dermatol; 2017 Nov; 153(11):1195-1197. PubMed ID: 28854317
    [No Abstract]   [Full Text] [Related]  

  • 4. Guselkumab in the treatment of severe hidradenitis suppurativa.
    Kovacs M; Podda M
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e140-e141. PubMed ID: 30480844
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.
    Ghias MH; Johnston AD; Kutner AJ; Micheletti RG; Hosgood HD; Cohen SR
    J Am Acad Dermatol; 2020 May; 82(5):1094-1101. PubMed ID: 31589948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.
    Schuch A; Fischer T; Boehner A; Biedermann T; Volz T
    Acta Derm Venereol; 2018 Jan; 98(1):151-152. PubMed ID: 28902952
    [No Abstract]   [Full Text] [Related]  

  • 7. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab for the treatment of hidradenitis suppurativa.
    Fernández-Vozmediano JM; Armario-Hita JC
    Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
    Tekin B; Salman A; Ergun T
    Indian J Dermatol Venereol Leprol; 2017; 83(5):615-617. PubMed ID: 28731016
    [No Abstract]   [Full Text] [Related]  

  • 10. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.
    Prussick L; Rothstein B; Joshipura D; Saraiya A; Turkowski Y; Abdat R; Alomran A; Zancanaro P; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
    Br J Dermatol; 2019 Sep; 181(3):609-611. PubMed ID: 30801662
    [No Abstract]   [Full Text] [Related]  

  • 11. Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
    Hotz C; Sbidian E; Ingen-Housz-Oro S; Chosidow O; Wolkenstein P
    Acta Derm Venereol; 2019 Nov; 99(12):1170-1171. PubMed ID: 31314122
    [No Abstract]   [Full Text] [Related]  

  • 12. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
    Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
    Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
    [No Abstract]   [Full Text] [Related]  

  • 14. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for the treatment of hidradenitis suppurativa.
    Lebwohl B; Sapadin AN
    J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S275-6. PubMed ID: 14576652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.
    Sotiriou E; Apalla Z; Vakirlis E; Ioannides D
    Eur J Dermatol; 2009; 19(2):180-1. PubMed ID: 19153066
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa.
    Braunberger TL; Lowes MA; Hamzavi IH
    Int J Dermatol; 2019 Sep; 58(9):1090-1091. PubMed ID: 30094834
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.
    Montero-Vilchez T; Martinez-Lopez A; Salvador-Rodriguez L; Arias-Santiago S; Molina-Leyva A
    Dermatol Ther; 2020 May; 33(3):e13456. PubMed ID: 32319172
    [No Abstract]   [Full Text] [Related]  

  • 19. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
    Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
    J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.